AbbVie

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie's BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, i

News

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren

News

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.

News

AbbVie files Vraylar as add-on therapy for depression in US

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the dr

News

Aldeyra builds case for troubled dry eye drug reproxalap

Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h

Genmab and AbbVie prep filings for lymphoma bispecific

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

AbbVie files Vraylar as add-on therapy for depression in US

Aldeyra builds case for troubled dry eye drug reproxalap

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AbbVie

Editor's Picks